LONDON (Alliance News) - Consort Medical PLC Monday said that UCB SA had received a recommendation from a European Medicines Agency's committee for its CIMZIA AutoClicks prefilled pens, which are based on technology licensed from Consort.
The EMA's Committee for Medicinal Products for Human Use has recommended the use of CIMZIA AutoClicks prefilled pens, used for the treatment of conditions like rheumatoid arthritis.
The AutoClicks pen is based on core technology licensed from Bespak, a subsidiary of Consort. It is expected that this technology will continue to underpin Consort's existing expectations, it said.
"We are delighted that this sophisticated Autoinjector product, that relies on Bespak technology at its core, has received a positive opinion from the EMA enabling its European roll-out in the very near term. This is another important milestone for Bespak injectable franchise with the approval of our first product into the high value and high growth biologics market," said Chief Executive Officer Jon Glenn in a statement.
Shares in Consort were up 1.2% at 1,076.49 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
